Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial (vol 41, pg 4852, 2023)

Author(s):
Goto, K.; Goto, Y.; Kubo, T.; Ninomiya, K.; Kim, S.W.; Planchard, D.; Ahn, M.J.; Smit, E.F.; Langen, A.J. de; Pérol, M.; Pons-Tostivint, E.; Novello, S.; Hayashi, H.; Shimizu, J.; Kim, D.W.; Kuo, C.H.; Yang, J.C.H.; Pereira, K.; Cheng, F.C.; Taguchi, A.; Cheng, Y.K.; Feng, W.Q.; Tsuchihashi, Z.; Jänne, P.A.
Published
2024
Publication type
Article / Letter to editor
Date issued
2024-02-01
Language
English
Is part of
Journal of Clinical Oncology (2024), Vol. 42, no. 4, p. 485-485
hdl
1887/4195704
doi
10.1200/JCO.23.02574
URL
https://ascopubs.org/doi/10.1200/JCO.23.02574